{"id":49783,"date":"2025-12-02T22:16:42","date_gmt":"2025-12-02T14:16:42","guid":{"rendered":"https:\/\/flcube.com\/?p=49783"},"modified":"2025-12-02T22:16:44","modified_gmt":"2025-12-02T14:16:44","slug":"abbisko-absk141-kras-g12d-inhibitor-secures-fda-ind-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49783","title":{"rendered":"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval"},"content":{"rendered":"\n<p><strong>Abbisko Cayman Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2256:HKG\">HKG: 2256<\/a>) announced that its Investigational New Drug (IND) application for <strong>ABSK141<\/strong>, an oral, highly potent and selective small molecule <strong>KRAS G12D inhibitor<\/strong>, has been approved by the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of patients with advanced solid tumors harboring the KRAS G12D mutation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-clearance-amp-development-status\">Regulatory Clearance &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Abbisko Cayman Limited (2256.HK)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ABSK141<\/td><\/tr><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>FDA IND approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors with KRAS G12D mutation<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Oral small molecule KRAS G12D inhibitor<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Phase 1 clinical study initiation planned for Q1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation<\/strong>: Novel oral small molecule KRAS G12D inhibitor independently designed and developed by Abbisko<\/li>\n\n\n\n<li><strong>Selectivity<\/strong>: Highly selective binding to mutant KRAS G12D protein, sparing wild-type KRAS<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Blocks downstream signaling pathways and inhibits tumor cell proliferation<\/li>\n\n\n\n<li><strong>Key Advantages<\/strong>: High potency, high selectivity, and potential best-in-class oral bioavailability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-validation\">Preclinical Validation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Parameter<\/th><th>Results<\/th><\/tr><\/thead><tbody><tr><td><strong>Oral Bioavailability<\/strong><\/td><td>Demonstrated potential best-in-class oral bioavailability across multiple animal species<\/td><\/tr><tr><td><strong>Anti-Tumor Efficacy<\/strong><\/td><td>Significant tumor regression in human tumor cell line derived xenograft (CDX) models<\/td><\/tr><tr><td><strong>Key Tumor Types<\/strong><\/td><td>Pancreatic Ductal Adenocarcinoma (PDAC) and Colorectal Cancer (CRC)<\/td><\/tr><tr><td><strong>Pharmacokinetics<\/strong><\/td><td>Favorable drug exposure and half-life supporting once-daily dosing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-outlook\">Market Opportunity &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KRAS G12D Prevalence<\/strong>: Represents approximately 30% of all KRAS mutations, with high incidence in pancreatic (45%) and colorectal (12%) cancers<\/li>\n\n\n\n<li><strong>Unmet Medical Need<\/strong>: No FDA-approved KRAS G12D targeted therapies currently exist, representing a significant commercial opportunity<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Abbisko joins a select group of biotech companies advancing KRAS G12D inhibitors into clinical development<\/li>\n\n\n\n<li><strong>Pipeline Validation<\/strong>: FDA IND approval underscores Abbisko&#8217;s discovery engine capabilities and strengthens its oncology franchise<\/li>\n\n\n\n<li><strong>Global Development<\/strong>: US trial initiation will be followed by potential expansion to China and other markets<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding ABSK141 development timelines, clinical outcomes, and market potential. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120102788_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025120102788_c.\"><\/object><a id=\"wp-block-file--media-79924b59-c3a0-4d48-839c-1413f3efff45\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120102788_c.pdf\">2025120102788_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025120102788_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-79924b59-c3a0-4d48-839c-1413f3efff45\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49786,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[186,16,62,921],"class_list":["post-49783","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-abbisko-therapeutics","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-2256"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141, an oral, highly potent and selective small molecule KRAS G12D inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced solid tumors harboring the KRAS G12D mutation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49783\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval\" \/>\n<meta property=\"og:description\" content=\"Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141, an oral, highly potent and selective small molecule KRAS G12D inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced solid tumors harboring the KRAS G12D mutation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49783\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T14:16:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-02T14:16:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0207.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49783#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49783\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval\",\"datePublished\":\"2025-12-02T14:16:42+00:00\",\"dateModified\":\"2025-12-02T14:16:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49783\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49783#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0207.webp\",\"keywords\":[\"Abbisko Therapeutics\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2256\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49783#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49783\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49783\",\"name\":\"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49783#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49783#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0207.webp\",\"datePublished\":\"2025-12-02T14:16:42+00:00\",\"dateModified\":\"2025-12-02T14:16:44+00:00\",\"description\":\"Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141, an oral, highly potent and selective small molecule KRAS G12D inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced solid tumors harboring the KRAS G12D mutation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49783#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49783\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49783#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0207.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0207.webp\",\"width\":1080,\"height\":608,\"caption\":\"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49783#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval - Insight, China&#039;s Pharmaceutical Industry","description":"Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141, an oral, highly potent and selective small molecule KRAS G12D inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced solid tumors harboring the KRAS G12D mutation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49783","og_locale":"en_US","og_type":"article","og_title":"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval","og_description":"Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141, an oral, highly potent and selective small molecule KRAS G12D inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced solid tumors harboring the KRAS G12D mutation.","og_url":"https:\/\/flcube.com\/?p=49783","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-02T14:16:42+00:00","article_modified_time":"2025-12-02T14:16:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0207.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49783#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49783"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval","datePublished":"2025-12-02T14:16:42+00:00","dateModified":"2025-12-02T14:16:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49783"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49783#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0207.webp","keywords":["Abbisko Therapeutics","Cancer","Clinical trial approval \/ initiation","HKG: 2256"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49783#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49783","url":"https:\/\/flcube.com\/?p=49783","name":"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49783#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49783#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0207.webp","datePublished":"2025-12-02T14:16:42+00:00","dateModified":"2025-12-02T14:16:44+00:00","description":"Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141, an oral, highly potent and selective small molecule KRAS G12D inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced solid tumors harboring the KRAS G12D mutation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49783#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49783"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49783#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0207.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0207.webp","width":1080,"height":608,"caption":"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49783#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0207.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49783"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49783\/revisions"}],"predecessor-version":[{"id":49787,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49783\/revisions\/49787"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49786"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}